Convergen, a biotechnology company creating targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, has announced...
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing...
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic...